SELLAS Life Sciences (SLS)
Nasdaq Market Closed
SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies that aim to address malignancies with significant unmet medical need. The company’s work centres on immuno-oncology and targeted treatment approaches, with programmes designed for patients whose cancers are difficult to treat using standard chemotherapy, radiation, surgery, or existing targeted medicines.
Its lead candidate, galinpepimut-S, commonly known as GPS, is a peptide-based immunotherapy directed at Wilms tumor 1, or WT1. WT1 is an antigen expressed in a range of haematologic cancers and solid tumours, making it a potential target for immune-based treatment strategies. GPS is designed to stimulate an immune response against WT1-expressing cancer cells and has been studied across multiple indications, including acute myeloid leukaemia and other cancer settings.
SELLAS is also developing GFH009, a selective small-molecule inhibitor of cyclin-dependent kinase 9, or CDK9. CDK9 is involved in transcriptional regulation and cancer cell survival pathways, and inhibition of this target is being explored as a way to disrupt growth signals in certain tumours. The company positions GFH009 as a targeted oncology candidate with potential relevance in both blood cancers and solid tumours.
As a late-stage biotechnology business, SELLAS does not operate like a commercial pharmaceutical company with diversified product sales. Its value is closely tied to clinical trial progress, regulatory outcomes, intellectual property, financing capacity, and the competitive landscape for oncology drug development.
Last updated
- Market Cap
- $2,514,930,621
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- $2,407,833,621
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 7 TIMES SQUARE, NEW YORK, NY, 10036
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $2,514,930,621
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $2,407,833,621
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 23.41
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -76.53
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -0.15
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -27.42%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -25.8%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 17.2
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 17.2
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 16.59
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $9,918,947
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 12.79
Income Statement
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 1M | 7.6M |
| Cost of revenue | 0 | 0 | 0 | 100K | 200K |
| Gross profit | — | — | — | 900K | 7.4M |
| Operating income | -28.27M | -31.51M | -37.87M | -41.95M | -25.29M |
| EBITDA | -28.27M | -31.51M | -37.87M | -31.95M | -19.59M |
| Net income | -26.86M | -30.88M | -37.34M | -41.3M | -20.7M |
| Income taxes | — | — | — | — | -237K |
| Interest expense | — | — | — | 317K | — |
| Other operating expenses | 0 | 0 | 0 | 10M | 5.7M |
| Total operating expenses | 28.27M | 31.51M | 37.87M | 42.85M | 32.69M |
| Basic EPS | -0.25 | -0.5 | -1.34 | -2.13 | -1.34 |
| Diluted EPS | -0.25 | -0.5 | -1.34 | -2.13 | -1.34 |
Balance Sheet
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Total assets | 78.35M | 19.43M | 6.22M | 20.94M | 26.28M |
| Total liabilities | 7.47M | 9.97M | 14.2M | 16.09M | 5.93M |
| Total equity | 70.87M | 9.47M | -7.98M | 4.85M | 20.35M |
| Cash & equivalents | 71.79M | 13.89M | 2.53M | 17.13M | 21.36M |
| Current assets | 75.11M | 16.23M | 3.07M | 17.66M | 22.94M |
| Current liabilities | 7.02M | 9.51M | 13.74M | 15.52M | 4.98M |
| Accounts payable | 2.95M | 3.5M | 5.64M | 3.36M | 2.14M |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M |
Cash Flow
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Operating cash flow | -28.39M | -35.4M | -31.41M | -28.31M | -26.02M |
| Investing cash flow | — | — | -5.5M | — | — |
| Financing cash flow | 86.3M | 46.76M | 22.32M | 24.08M | 12.07M |
| Change in cash | 57.91M | 11.36M | -14.6M | -4.23M | -13.95M |
| Net income | -26.86M | -30.88M | -37.34M | -41.3M | -20.7M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-8 — SELLAS Life Sciences Group, Inc. | View Filing | |
| form 4 | Form 4 — Stergiou Angelos M. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | DEF 14A — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | DEFA14A — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | ARS — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | S-3ASR — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 10-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Wasman Jane | View Filing | |
| form 4 | Form 4 — Kalin Katherine Bach | View Filing | |
| form 4 | Form 4 — Burns John Thomas | View Filing | |
| form 4 | Form 4 — CICIC DRAGAN | View Filing | |
| form 4 | Form 4 — SCHEINBERG DAVID A | View Filing | |
| form 4 | Form 4 — VAN NOSTRAND ROBERT L | View Filing | |
| form 4 | Form 4 — Varian John | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| form 4 | Form 4 — Stergiou Angelos M. | View Filing | |
| form 4 | Form 4 — Burns John Thomas | View Filing | |
| form 4 | Form 4 — CICIC DRAGAN | View Filing | |
| edgar index | EFFECT — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | CORRESP — SELLAS Life Sciences Group, Inc. | View Filing | |
| form 4 | Form 4 — Kalin Katherine Bach | View Filing | |
| edgar index | SCHEDULE 13G — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 10-Q — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 424B5 — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | S-3 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | S-8 — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 10-Q — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 8-K — SELLAS Life Sciences Group, Inc. | View Filing | |
| edgar index | 4 — SELLAS Life Sciences Group, Inc. | View Filing | |
| form 4 | Form 4 — VAN NOSTRAND ROBERT L | View Filing | |
| edgar index | DEFA14A — SELLAS Life Sciences Group, Inc. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free